Table 3.
Main effects and treatment-specific effects of selected interleukin SNPs
| RSID | Gene Symbol |
Role/Function in Cancer (reference) |
Endpoint | Main effects |
By Treatment4 |
||
|---|---|---|---|---|---|---|---|
| mHR (95% CI)1 | P-value2 | Surgery | Surgery plus ACT | ||||
| rs1800587 | IL1A | Tumor invasion and angiogenesis (43) |
OS DFS TTR |
0.80 (0.65, 0.99) 0.75 (0.59, 0.95) 0.81 (0.57, 1.15) |
0.045 0.017 0.2373 |
0.94 (0.54, 1.64) 0.78 (0.47, 1.32) 0.59 (0.22, 1.58) |
0.45 (0.27, 0.76)
0.50 (0.32, 0.79) 0.56 (0.31, 1.00) |
| rs1143634 | IL1B | Tumor invasion and angiogenesis (43) |
OS DFS TTR |
0.78 (0.63, 0.98) 0.73 (0.57, 0.93) 0.71 (0.49, 1.02) |
0.033 0.011 0.0653 |
0.69 (0.39, 1.23) 0.59 (0.34, 1.02) 0.30 (0.09, 1.05) |
0.63 (0.37, 1.05) 0.68 (0.44, 1.07) 0.68 (0.38, 1.22) |
| rs12506479 | IL8 | Angiogenesis; cell proliferation and survival (44) |
OS DFS TTR |
1.35 (1.09, 1.68) 1.29 (1.01, 1.64) 1.02 (0.72, 1.46) |
0.006 0.040 0.9023 |
2.01 (1.15, 3.49) 1.87 (1.11, 3.15) 1.42 (0.52, 3.93) |
1.08 (0.65, 1.80) 1.06 (0.68, 1.66) 0.90 (0.50, 1.60) |
| rs662959 | IL12A | Anti-angiogenesis and anti-metastasis (34) |
OS DFS TTR |
1.15 (0.90, 1.48) 1.41 (1.08, 1.83) 1.49 (1.01, 2.19) |
0.2613 0.012 0.045 |
1.79 (0.96, 3.34) 2.03 (1.15, 3.62) 2.42 (0.88, 6.69) |
1.53 (0.88, 2.67) 1.94 (1.20, 3.12) 1.84 (0.99, 3.39) |
| rs1881457 | IL13 | Tumorigenesis, invasion, and metastasis (45) |
OS DFS TTR |
1.10 (0.87, 1.38) 1.29 (1.00, 1.66) 1.49 (1.03, 2.16) |
0.4353 0.049 0.034 |
0.87 (0.48, 1.60) 0.81 (0.45, 1.44) 0.56 (0.15, 2.05) |
1.56 (0.90, 2.68) 1.66 (1.05, 2.63) 2.07 (1.14, 3.77) |
| rs7170924 | IL16 | Tumor progression, angiogenesis (28) |
OS DFS TTR |
0.82 (0.65, 1.02) 0.65 (0.50, 0.83) 0.79 (0.55, 1.13) |
0.080 0.001 0.201 |
0.51 (0.29, 0.90) 0.49 (0.29, 0.84) 0.82 (0.32, 2.09) |
0.71 (0.41, 1.21) 0.60 (0.37, 0.96) 0.69 (0.38, 1.27) |
Abbreviations: mHR, multivariable hazard ratio; CI, confidence interval; ACT, adjuvant chemotherapy; OS, overall survival; DFS, disease-free survival; TTR, time to recurrence
Bold font indicates a statistically significant HR
1
Adjusted for age, gender, race, smoking status, stage, histology, and first course treatment.
2
P-value from the Cox Proportional Hazard model
3
Not statistically significantly associated with the endpoint and were not included in Table 2.
4
Among IA to IIIB patients only